{"entity":{"id":"nct06782555","kind":"trial","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","aka":[],"tldr":"A phase 1/2 trial of Zalifrelimab and Balstilimab in prostate cancer, head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma, run by ImmunoGenesis, now recruiting.","summary":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab is a phase 1/2 interventional study registered as NCT06782555 by ImmunoGenesis, with 71 participants planned, started 2025-01-08 and due to reach its primary completion in 2027-10. Interventions recorded: Evofosfamide, Zalifrelimab and Balstilimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06782555","url":"https://clinicaltrials.gov/study/NCT06782555"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","head-and-neck","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["zalifrelimab","balstilimab"],"companies":["agenus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06782555","phase":"1/2","setting":"A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab in Patients with Advanced Solid Malignancies","sponsor":"ImmunoGenesis","enrolled":71,"outcomes":[]},"route":"/trials/nct06782555/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/"},{"id":"zalifrelimab","kind":"drug","name":"Zalifrelimab","route":"/drugs/zalifrelimab/"}],"company":[{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/"}]}}